Beacon Hospice, An Amedisys Company 25 Hampshire Ave Suite 272, Portsmouth, NH, 03801 | |
(603) 433-4280 |
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
Name | Beacon Hospice, An Amedisys Company |
---|---|
Location | 25 Hampshire Ave Suite 272, Portsmouth, New Hampshire |
Hospice ID | 301526 |
Category | Freestanding Hospice |
Ownership Type | Other |
Profit Type | OTHER |
SSA county code | 070 |
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
NPI Number | 1023193703 |
Organization Name | Beacon Hospice, Llc |
Address | 25 New Hampshire Ave Portsmouth, New Hampshire, 03801 |
Phone Number | (603)433-2480 |
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 97.7 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 97.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 87.7 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 97.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 80.4 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 96.8 | 93.3 |
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
Home Health Aides | 6 |
Counselors | 1 |
Medical Social Workers | 1 |
Registered Nurses | 7 |
Other Personnel | 7 |
Total Employees | 22 |
---|
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
Others | 2 |
Total Volunteers | 2 |
---|
News Archive
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
"In the run up to the U.N. summit on non-communicable diseases (NCDs), there are fears that industry interests might be trumping evidence-based public health interventions," BMJ reports.
The Treatabolome project is a research initiative to develop a freely available, interoperable online platform dedicated to disseminating rare disease and gene-specific treatment information to healthcare professionals regardless of their level of specialized expertise.
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Ambulances with specialized staff and equipment to provide rapid stroke treatment report financial difficulties due to limited reimbursement from health care insurers, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021.
› Verified 6 days ago
Beacon Hospice, An Amedisys Company Location: 25 Hampshire Ave Suite 272, Portsmouth, New Hampshire, 03801 Phone: (603) 433-4280 |